Beijing, Aug. 24 (Xinhua News Agency, reported by Xia Ke) - Sino Biopharmaceutical Limited (hereinafter referred to as Sino Biopharm) held a first-half results conference in Beijing on the 24th. Its semi-annual results show that the first half-year operating revenue of Sino Biopharm reached 15.19 billion RMB, an increase of 5.9% year-on-year. Chairwoman of the Board of Directors of Sino Biopharm, Miss Tse, Theresa Y Y, said that the company will promote comprehensive innovation and transformation by independent research and development and external introduction in the future, and strive to achieve the strategic goal of HK$ 100 billion revenue in 2030.

Miss Tse, Theresa Y Y introduced that in the next three years, Sino Biopharm expects to have nearly 80 products on the market, as well as more than 10 heavyweight projects, which will become an important growth engine for the company and help achieve double-digit compound growth of revenue.

It is reported that since 2022, Sino Biopharm has established four strategies of "organizational integration, comprehensive innovation, digitalization and internationalization". On June 23, 2022, Sino Biopharm announced the proposed acquisition of NASDAQ-listed company F-star for $161 million, which would be an important milestone in the company's dual antibodies platform. If the transaction is finally completed, it will give Sino Biopharm a cutting-edge dual antibodies platform technology and an international clinical R&D team.